




RealRate

# PHARMACEUTICAL 2018

## NightHawk Biosciences Inc. Rank 256 of 342





RealRate

# PHARMACEUTICAL 2018

## NightHawk Biosciences Inc. Rank 256 of 342



The relative strengths and weaknesses of NightHawk Biosciences Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of NightHawk Biosciences Inc. compared to the market average is the variable Other Assets, increasing the Economic Capital Ratio by 47% points. The greatest weakness of NightHawk Biosciences Inc. is the variable Liabilities, Current, reducing the Economic Capital Ratio by 60% points.

The company's Economic Capital Ratio, given in the ranking table, is -13%, being 58% points below the market average of 46%.

Input Variable	Value in 1000 USD
Assets, Current	11,745
Cost of Goods Sold	0
Intangible Assets	2,189
Liabilities, Current	10,336
Liabilities, Non-Current	161
Other Assets	5,968
Other Compr. Net Income	474
Other Expenses	-585
Other Liabilities	3,912
Other Net Income	123
Other Revenues	1,520
Property and Equipment	287
Research and Development	8,268
Selling, General and Administrative Expense	6,371

Output Variable	Value in 1000 USD
Assets	20,189
Liabilities	14,409
Expenses	14,053
Revenues	1,520
Stockholders Equity	5,781
Net Income	-12,410
Comprehensive Net Income	-12,173
Economic Capital Ratio	-13%